Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards?
No Thumbnail Available
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Description
<p>Immunotherapy, in the form of immune checkpoint inhibitors (ICI), has shown activity in metastatic urothelial bladder carcinoma, resulting in the approval of several ICI agents in the first- and second-line settings. This has led to an increased interest in studying their efficacy in the neoadjuvant setting for muscle invasive disease – an area of significant unmet need. This non-systematic review will look at the evidence supporting the use of ICI in the neoadjuvant setting for this tumor, results of early-phase studies, ongoing trials, and possible future applications for these drugs.</p>
Keywords
bladder cancer, immune checkpoint inhibitor, immunotherapy, muscle invasive, neoadjuvant, SDG 3 - Good Health and Well-being